-
Something wrong with this record ?
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
Y. Lin, L. Qiu, S. Usmani, CW. Joo, L. Costa, B. Derman, J. Du, H. Einsele, C. Fernandez de Larrea, R. Hajek, PJ. Ho, E. Kastritis, J. Martinez-Lopez, MV. Mateos, J. Mikhael, P. Moreau, C. Nagarajan, A. Nooka, M. O'Dwyer, F. Schjesvold, S....
Language English Country England, Great Britain
Document type Journal Article, Review, Practice Guideline
NLK
ProQuest Central
from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest)
from 2000-09-01 to 2 months ago
Public Health Database (ProQuest)
from 2000-09-01 to 2 months ago
- MeSH
- Receptors, Chimeric Antigen * immunology therapeutic use MeSH
- Immunotherapy, Adoptive * adverse effects MeSH
- Consensus * MeSH
- Humans MeSH
- Multiple Myeloma * therapy immunology MeSH
- Receptors, Antigen, T-Cell therapeutic use immunology MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Practice Guideline MeSH
Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.
Department of Haematology Singapore General Hospital Singapore
Department of Hematology Amsterdam University Medical Center Amsterdam Netherlands
Department of Hematology and Oncology University of Chicago Chicago IL USA
Department of Hematology Cancer Center Clinica Universidad de Navarra Pamplona Navarra Spain
Department of Hematology Mayo Clinic Rochester MN USA
Department of Hematology Oncology University of Alabama at Birmingham Birmingham AL USA
Department of Hematology University Hospital of Nantes Nantes France
Department of Hematology University of California San Francisco CA USA
Department of Hematooncology Faculty of Medicine University Ostrava Ostrava Czech Republic
Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Department of Internal Medicine 2 University Hospital Wurzburg Germany
Department of Medical Oncology National University Cancer Institute Singapore
Department of Medicine and Department of Haematology National University of Ireland Galway Ireland
Department of Medicine Harvard University Cambridge MA USA
Hospital Universitario 12 de Octubre Department of Medicine Complutense University CNIO Madrid Spain
Hospital Universitario de Salamanca Salamanca Spain
Institute of Hematology Royal Prince Alfred Hospital University of Sydney Sydney NSW Australia
Memorial Sloan Kettering Cancer Center New York NY USA
Oslo Myeloma Center Oslo University Hospital Oslo Norway
School of Medicine Stanford University San Francisco CA USA
Simmons Comprehensive Cancer Center Dallas TX USA
Translational Genomics Research Institute City of Hope Cancer Center Phoenix AZ USA
University of Texas Southwestern Medical Center Dallas TX USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019564
- 003
- CZ-PrNML
- 005
- 20241024110630.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(24)00094-9 $2 doi
- 035 __
- $a (PubMed)38821074
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lin, Yi $u Department of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: lin.yi@mayo.edu
- 245 10
- $a Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee / $c Y. Lin, L. Qiu, S. Usmani, CW. Joo, L. Costa, B. Derman, J. Du, H. Einsele, C. Fernandez de Larrea, R. Hajek, PJ. Ho, E. Kastritis, J. Martinez-Lopez, MV. Mateos, J. Mikhael, P. Moreau, C. Nagarajan, A. Nooka, M. O'Dwyer, F. Schjesvold, S. Sidana, NW. van de Donk, K. Weisel, S. Zweegman, N. Raje, PR. Otero, LD. Anderson, S. Kumar, T. Martin, International Myeloma Working Group
- 520 9_
- $a Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.
- 650 12
- $a mnohočetný myelom $x terapie $x imunologie $7 D009101
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a imunoterapie adoptivní $x škodlivé účinky $7 D016219
- 650 12
- $a chimerické antigenní receptory $x imunologie $x terapeutické užití $7 D000076962
- 650 12
- $a konsensus $7 D032921
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a receptory antigenů T-buněk $x terapeutické užití $x imunologie $7 D011948
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Qiu, Lugui $u National Clinical Research Center for Blood Diseases and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Pekin Union Medical College, Tianjin, China
- 700 1_
- $a Usmani, Saad $u Memorial Sloan Kettering Cancer Center, New York, NY, USA
- 700 1_
- $a Joo, Chng Wee $u Department of Medical Oncology, National University Cancer Institute, Singapore
- 700 1_
- $a Costa, Luciano $u Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
- 700 1_
- $a Derman, Benjamin $u Department of Hematology and Oncology, University of Chicago, Chicago, IL, USA
- 700 1_
- $a Du, Juan $u Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China
- 700 1_
- $a Einsele, Hermann $u Department of Internal Medicine II, University Hospital, Wurzburg, Germany
- 700 1_
- $a Fernandez de Larrea, Carlos $u Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
- 700 1_
- $a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hematooncology, Faculty of Medicine, University Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Ho, P Joy $u Institute of Hematology, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Kastritis, Efstathios $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Martinez-Lopez, Joaquin $u Hospital Universitario 12 de Octubre, Department of Medicine, Complutense University, CNIO, Madrid, Spain
- 700 1_
- $a Mateos, Maria-Victoria $u Hospital Universitario de Salamanca, Salamanca, Spain
- 700 1_
- $a Mikhael, Joseph $u Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA
- 700 1_
- $a Moreau, Philippe $u Department of Hematology, University Hospital of Nantes, Nantes, France
- 700 1_
- $a Nagarajan, Chandramouli $u Department of Haematology, Singapore General Hospital, Singapore
- 700 1_
- $a Nooka, Ajay $u Winship Cancer Institute of Emory University, Atlanta, GA, USA
- 700 1_
- $a O'Dwyer, Michael $u Department of Medicine and Department of Haematology, National University of Ireland, Galway, Ireland
- 700 1_
- $a Schjesvold, Fredrik $u Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Sidana, Surbhi $u School of Medicine, Stanford University, San Francisco, CA, USA
- 700 1_
- $a van de Donk, Niels Wcj $u Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands
- 700 1_
- $a Weisel, Katja $u Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Zweegman, Sonja $u Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands
- 700 1_
- $a Raje, Noopur $u Department of Medicine, Harvard University, Cambridge, MA, USA
- 700 1_
- $a Otero, Paula Rodriguez $u Department of Hematology, Cancer Center Clinica Universidad de Navarra, Pamplona, Navarra, Spain
- 700 1_
- $a Anderson, Larry D $u Simmons Comprehensive Cancer Center, Dallas, TX, USA; University of Texas Southwestern Medical Center, Dallas, TX, USA
- 700 1_
- $a Kumar, Shaji $u Department of Hematology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Martin, Tom $u Department of Hematology, University of California, San Francisco, CA, USA
- 710 2_
- $a International Myeloma Working Group
- 773 0_
- $w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 25, č. 8 (2024), s. e374-e387
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38821074 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110624 $b ABA008
- 999 __
- $a ok $b bmc $g 2202034 $s 1231537
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 25 $c 8 $d e374-e387 $e 20240528 $i 1474-5488 $m The Lancet. Oncology $n Lancet Oncol $x MED00011558
- LZP __
- $a Pubmed-20241015
